West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Bre... von Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E, Kreipe, Hans H, Harbeck, Nadia

Volltext

Abstract P6-13-02: Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-prognosis advanced breast cancer (aBC): Subgroup analyses of the German AVANTI observational... von Mueller, V, Jakob, A, Aktas, B, Pott, D, Grafe, A, Jungberg, P, Maerz, W, Fett, W, Bruch, H-R, Klare, P, Boller, E, Hoefflin, S, Schneeweiss, A

Volltext

Impact of age on the safety and efficacy of bevacizumab (BEV)-containing therapy in patients (pts) with primary ovarian cancer (OC): Analyses of the OTILIA German non-interventiona... von Mustea, A., Wimberger, P., Oskay-Oezcelik, G., Jungberg, P., Meinerz, W., Reichert, D., Janssen, J., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Mueller, M., Sehouli, J.

Volltext

Abstract P5-21-02: Hormone receptor status and endocrine therapy in a prospective observation study on trastuzumab (Herceptin®) in the adjuvant treatment of breast cancer von Dall, P, Friedrichs, K, Petersen, V, Hinke, A, Brucker, C, Schmidt, P, von der Assen, A, Jungberg, P, Bohnsteen, B

Volltext